BIOGEN INC. - COMMON STOCK

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

25 9 2024 16:06:38 提供 NetDania Notify

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

24 9 2024 01:00:00 提供 Nasdaq GlobeNewswire

Biogen Board Appoints Two New Independent Directors

12 9 2024 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

04 9 2024 07:30:34 提供 Nasdaq GlobeNewswire

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alzheimer’s Association International Conference (AAIC) 2024

30 7 2024 17:15:17 提供 Nasdaq GlobeNewswire

Biogen, Beckman Coulter and Fujirebio to Collaborate on Blood-Based Biomarkers and Test for Tau Pathology in Alzheimer’s Disease

30 7 2024 07:30:00 提供 Nasdaq GlobeNewswire

Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease in the European Union

26 7 2024 07:20:38 提供 Nasdaq GlobeNewswire

Biogen Completes Acquisition of Human Immunology Biosciences

02 7 2024 09:16:51 提供 Nasdaq GlobeNewswire

“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China

27 6 2024 19:39:36 提供 Nasdaq GlobeNewswire

TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®, Approved in the European Union

24 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

09 6 2024 19:37:43 提供 Nasdaq GlobeNewswire

Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel

03 6 2024 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS

30 5 2024 16:51:04 提供 Nasdaq GlobeNewswire

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

22 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

16 5 2024 07:30:14 提供 Nasdaq GlobeNewswire

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track Status

14 5 2024 19:33:37 提供 Nasdaq GlobeNewswire

Biogen Reports Progress on Corporate Responsibility Priorities

02 5 2024 07:30:00 提供 Nasdaq GlobeNewswire

Biogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®

25 4 2024 16:05:00 提供 Nasdaq GlobeNewswire

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

19 4 2024 09:50:39 提供 NetDania Notify

NetDania - New 12 months Low: BIOGEN INC. - COMMON STOCK

18 4 2024 09:45:07 提供 NetDania Notify